Sarah Cannon Research Institute | Strategic Alliance Partners

October 01, 2021

Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.

September 29, 2021

Sarah Cannon recently opened its newest drug development unit in collaboration with Florida Cancer Specialists & Research Institute and The University of Central Florida College of Medicine in Lake Nona, Flordia.

August 03, 2021

The 2021 ASCO Annual Meeting was chock full of practice-changing, practice-affirming, and exciting preliminary research in non–small cell lung cancer, said Melissa Johnson, MD.

June 24, 2021

Sarah Cannon announced today that Navneet Majhail, MD, MS, FASTCT has been named Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant and Cellular Therapy Network.

April 19, 2021

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

March 11, 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

February 23, 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

February 16, 2021

Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.

February 01, 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

February 01, 2021

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

January 25, 2021

David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.

January 25, 2021

Johanna C. Bendell, MD, moderates a peer exchange with fellow experts to discuss differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma, and treatment options for patients with BRAF-mutant, microsatellite instability–high colorectal cancer.

January 22, 2021

David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.

January 21, 2021

Erika P. Hamilton, MD, discusses the rationale behind examining OP-1250 in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

January 21, 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.

January 12, 2021

Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.

December 18, 2020

December 18, 2020 - Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research.

October 14, 2020

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

October 08, 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

October 06, 2020

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.